We use cookies to provide you a better experience. By continuing to use this website, you consent to the use of cookies in accordance with our Cookie Policy.

Healthcare

Delivering solutions in M&A, Capital Raising, and Restructuring

Healthcare Investment Banking Group

Finding financial solutions across every sector of the healthcare ecosystem.

A full-service healthcare investment banking practice offering a best-in-class combination of deep sector knowledge, strong industry relationships, and broad product expertise.

Stifel’s Global Healthcare Investment Banking Group is comprised of 47 professionals covering all segments of the healthcare industry. The team, located in New York, San Francisco, London, Toronto, and Montreal, has substantial experience in assisting companies with all types of financing and M&A assignments. The Global Healthcare Group is dedicated to building long-term relationships with its clients through senior level attention. Since the formation of the Global Healthcare Group in Q4 2010, the team have helped raise over $79.1 billion for over 225 healthcare companies in over 440 transactions. Over the same period, members of the Global Healthcare Group have advised on over 105 announced M&A transactions, including over 30 cross-border assignments.

Our team provides clients with strategic advisory and capital-raising services designed to support growth companies and their investors during all stages of their development. We offer equity and debt capital markets services, including book running leading IPOs, follow-ons, and convertible note issuances. The Global Healthcare Group is supported by M&A advisory with extensive cross-border expertise, access to private capital markets through SPACs and 144A solutions, as well as activism defense and restructuring.

Areas of Expertise

Biopharma

The biopharma sector is advancing at an unprecedented pace, driven by innovation and growth from small to large companies across all stages of development and therapeutic areas. Stifel’s Biopharma team is uniquely positioned to serve the needs of our clients in all types of financing and M&A assignments via our deep understanding of the biopharma landscape, and our extensive relationships and transaction experience.

Healthcare Services

The healthcare services landscape is constantly shifting, driven by changes in regulations, reimbursement, and advancements in technology. Stifel’s Healthcare Services Team works to stay abreast of these changes and is ideally positioned to serve the needs of our clients in all types of financing and M&A assignments via relationships, recent mandates, and years of thought leadership across a broad range of healthcare sub-sectors including Alternate Site, Behavioral Health, Payor Services, Pharma Services, and Physician Groups.

HealthTech

Technologies are rapidly advancing the automation of workflows across the healthcare ecosystem, the development and efficacy of treatments, and the way in which care is provided in-person and remotely.  Stifel’s Healthcare Technology team brings a wealth of M&A and financing experience advising companies delivering software, digital health, data-driven, and technology-enabled solutions to providers, payors, pharmaceutical companies, and patients.

Medtech

The Medtech sector is advancing at an unprecedented pace, driven by innovation and growth from small to large companies across all Medtech subsectors. Stifel’s Medtech team is uniquely positioned to serve the needs of our clients in all types of financing and M&A assignments via our deep understanding of the Medtech landscape, and our extensive relationships and transaction experience.

Tools & Diagnostics

The life science tools & diagnostics sector is transforming at amazing speeds.  Enabled by a broad array of new technologies, our ability to better understand all facets of the human genome has improved exponentially; all the while being done at greater efficiency and dramatically reduced costs. This widening knowledge set is enabling faster and more productive drug discovery, disease diagnosis and AI-enabled prognostic clinical capabilities.  Stifel’s Life Science Tools & Diagnostics team is uniquely positioned to serve the needs of our clients in all types of financing and M&A assignments via our broad domain expertise, deep understanding of the competitive landscape, and our extensive relationships and transaction experience.

Read Our Latest Thoughts on Investment Banking in the Healthcare Sector

Learn More

Notable Transactions

Mineralys Follow-on

$ 175,000,000

Follow-on Offering
Biopharma Mar 2025
Kestra IPO

$ 202,000,000

Initial Public Offering
Medtech Mar 2025
Sionna IPO

$ 219,200,000

Initial Public Offering
Biopharma Feb 2025
GH  Research Follow-on

$ 150,000,000

Follow-on Offering
Biopharma Feb 2025
Radar_EIDO MA

Mergers & Acquisitions
Healthcare Feb 2025
Uniqure

$ 75,000,000

Follow-on Offering
Biopharma Jan 2025
Pieris_Palvella MA

Mergers & Acquisitions
HealthTech Dec 2024
Trevi Therapeutics Registered Direct

$ 50,000,000

Registered Direct
Biopharma Dec 2024
CG Oncology Follow-on

$ 257,600,000

Follow-on Offering
Biopharma Dec 2024
Nabriva HKF MA

Mergers & Acquisitions
HealthTech Dec 2024
Janux

$ 402,500,000

Follow-on Offering
Biopharma Dec 2024
KalVista Registered Direct & PIPE

$ 60,000,000

Registered Direct & PIPE
Biopharma Nov 2024
Bora Pharmaceuticals_Pyros Pharmaceuticals MA

Mergers & Acquisitions
Biopharma Oct 2024
Biomapas_Carbyne MA

Mergers & Acquisitions
Healthcare Services Oct 2024
Nuvalent Follow-on

$ 575,000,000

Follow-on Offering
Biopharma Sep 2024
Bicara IPO

$ 362,250,000

Initial Public Offering
Biopharma Sep 2024
MBX IPO

$ 187,680,000

Initial Public Offering
Biopharma Sep 2024
Viridian Follow-on

$ 258,750,000

Follow-on Offering
Biopharma Sep 2024
Oruka PIPE

$ 200,536,320

PIPE
Biopharma Sep 2024
Relay Pharmaceuticals Follow-on

$ 200,000,000

Follow-on Offering
Biopharma Sep 2024
Kymera CMO

$ 258,750,000

Confidentially Marketed Follow-on Offering
Biopharma Aug 2024
Phathom Registered Direct

$ 130,000,000

Registered Direct
Biopharma Aug 2024
SAiba_Boehringer MA

Mergers & Acquisitions
Healthcare, Biopharma Aug 2024
Orthopediatrics Senior Notes

$ 100,000,000

Convertible Notes & Senior Secured Term Loan
Medtech Aug 2024
Precigen Follow-on

$ 33,900,000

Follow-on Offering
Biopharma Aug 2024
Adagio_Ayra

$ 128,000,000

SPAC Merger
Medtech Jul 2024
Akston_Dechra

Mergers & Acquisitions
Healthcare Jul 2024
Endomag_Hologic

$ 310,000,000

Mergers & Acquisitions
Medtech, Healthcare Jul 2024
Nabriva Therapeutics_Meithal MA

Mergers & Acquisitions
Biopharma Jul 2024
Valenz_HealthcareBook MA

Mergers & Acquisitions
HealthTech Jul 2024
Onward Medical SCF

€ 52,500,000

Secured Credit Facility
Healthcare Jun 2024
Rapport Therapeutics IPO

$ 174,400,000

Initial Public Offering
Biopharma Jun 2024
Celcuity Registered Direct

$ 60,000,000

Registered Direct
Biopharma May 2024
Dyne Follow-on

$ 374,325,000

Follow-on Offering
Biopharma May 2024
Abeona Registered Direct

$ 75,000,000

Registered Direct
Biopharma May 2024
Sientra Agg Indebtedness 0424

$ 94,300,000

Aggregate Indebtedness
Medtech Apr 2024
Sientra Tiger Nuance MA 0424

$ 121,600,000

Has Sold Assets to
Medtech Apr 2024
Cullinan Therapeutics

$ 280,000,000

PIPE
Biopharma Apr 2024
Nurix Therapeutics

$ 201,250,000

Confidentially Marketed Follow-on Offering
Biopharma Apr 2024
Contineum Therapeutics IPO

$ 110,000,000

Initial Public Offering
Biopharma Apr 2024
Upsher-Smith_Bora Pharmaceuticals

Mergers & Acquisitions
Biopharma Apr 2024
NervGen Pharma Corp Follow-on

C$ 23,011,788

Follow-on Offering
Healthcare & Special Situations Mar 2024
Avalo_AlmataBio_MA_March

Mergers & Acquisitions
Biopharma Mar 2024
Nkarta Registered Direct

$ 240,100,310

Registered Direct
Biopharma Mar 2024
Geron Registered Direct

$ 150,000,000

Registered Direct
Biopharma Mar 2024
Spyre Therapeutics PIPE

$ 180,000,000

PIPE
Biopharma Mar 2024
Apogee Therapeutics

$ 482,999,902

Follow-on Offering
Biopharma Mar 2024
Regenxbio Follow-on

$ 140,000,000

Follow-on Offering
Biopharma Mar 2024
South Coast Retina_ Retina Consultants of America MA

Mergers & Acquisitions
Healthcare Services Mar 2024
Avacta

£ 31,000,000

Follow-on Offering
Healthcare Mar 2024
Viking Follow-on

$ 632,540,250

Follow-on Offering
Biopharma Feb 2024
Dario Health

$ 34,400,000

Mergers & Acquisitions
HealthTech Feb 2024
Numinus Follow-on

C$ 6,000,000

Follow-on Offering
Biopharma Feb 2024
KalVista FO

$ 160,125,000

Confidentially Marketed Follow-on Offering
Biopharma Feb 2024
Dyne Therapeutics

$ 345,144,000

Follow-on Offering
Biopharma Jan 2024
Syndax CMO

$ 230,000,000

Confidentially Marketed Follow-on Offering
Biopharma Dec 2023
Cibus Registered Direct

$ 20,300,000

Registered Direct
HealthTech Dec 2023
Spyre PIPE

$ 180,000,000

PIPE
Biopharma Dec 2023
Vanda_Johnson & Johnson MA

$ 100,000,000

Mergers & Acquisitions
Biopharma Dec 2023
Xenon

$ 300,000,000

Confidentially Marketed Follow-on Offering
Biopharma Nov 2023
M8 Pharmaceuticals_Acino

Mergers & Acquisitions
Biopharma Nov 2023
Teijin_Ascendis

$ 245,000,000+

In-Licensing
Biopharma Nov 2023
Medstrat_Zimmer Biomet MA

Mergers & Acquisitions
HealthTech Nov 2023
Lexeo IPO

$ 111,536,216

Initial Public Offering
Biopharma Nov 2023
Alphatec CMO

$ 150,150,000

Confidentially Marketed Follow-on Offering
Medtech Oct 2023
Cerevel CMO

$ 517,500,000

Confidentially Marketed Follow-on Offering
Biopharma Oct 2023
Biocorp

€ 154,430,010

Mergers & Acquisitions
Medtech Oct 2023
Vistagen Registered Direct

$ 100,000,000

Registered Direct
Biopharma Oct 2023
Immunome_Morphimmune MA

$ 90,833,010

Mergers & Acquisitions
Biopharma Oct 2023
Infirst_Carlin MA

Mergers & Acquisitions
Healthcare Sep 2023
Hillevax CMO

$ 115,000,000

Confidentially marketed Follow-on Offering
Biopharma Sep 2023
Neumora IPO

$ 250,070,000

Initial Public Offering
Biopharma Sep 2023
Acumen FO

$ 130,000,000

Follow-on Offering
Biopharma Jul 2023
Apogee IPO

$ 345,057,500

Initial Public Offering
Biopharma Jul 2023
Kooth Follow-on

£ 10,000,000

Equity Placing
Healthcare Jul 2023
IGM Biosciences

$ 120,000,000

Confidentially Marketed Follow-on Offering
Biopharma Jun 2023
Disc Medicine Follow-on

$ 137,200,000

Follow-on Offering
Biopharma Jun 2023
Tricida Chapter 11

$ 200,000,000

Chapter 11 Restructuring
Biopharma Jun 2023
30 Technology_Convatec MA

£ 176,000,000

Mergers & Acquisitions
Medtech Apr 2023
Karuna Follow-on

$ 460,000,000

Follow-on Offering
Biopharma Mar 2023
Mineralys IPO

$ 220,800,000

Initial Public Offering
Biopharma Feb 2023
Renalytix PIPE

$ 20,300,000

PIPE
Healthcare Feb 2023
Treace Medical CMO

$ 100,000,000

Confidentially Marketed Follow-on Offering
Medtech Feb 2023
Geron Follow-on

$ 227,843,965

Follow-on Offering
Biopharma Jan 2023
Bioassay_ReactionBiology

Mergers & Acquisitions
Healthcare Dec 2022
Cutera

$ 120,000,000

Convertible Notes
Medtech Dec 2022
VOR Registered Direct

$ 115,799,748

Registered Direct & PIPE
Biopharma Dec 2022
X4 Pharmaceuticals

$ 65,010,000

Confidentially Marketed Follow-on Offering
Biopharma Dec 2022
Unimed_ZCG

Mergers & Acquisitions
Maritime Services, Healthcare Services Dec 2022
Iveric Bio CMO

$ 300,375,000

Confidentially Marketed Follow-on Offering
Biopharma Dec 2022
Purigen Biosystems_Bionano

$ 64,000,000

Mergers & Acquisitions
Tools & Diagnostics Nov 2022
OmniAb_Avista MA

$ 850,000,000

Mergers & Acquisitions
Biopharma Nov 2022
Silkroad Follow-on

$ 115,000,000

Follow-on Offering
Medtech Oct 2022
Avacta Group Convertible Bond FO

£ 64,000,000

Convertible Bond & Follow-on Offering
Healthcare Services Oct 2022
Trevi CMO

$ 58,079,577

Confidentially Marketed Follow-on Offering
Biopharma Sep 2022
Rhythm CMO

$ 124,800,000

Confidentially Marketed Follow-on Offering
Biopharma Sep 2022
Medpharmex_Dechra MA

$ 260,000,000

Mergers & Acquisitions
Healthcare Services Aug 2022
Fulcrum Therapeutics CMO

$ 84,249,986

Confidentially Marketed Follow-on Offering
Biopharma Aug 2022
Orthopediatrics CMO

$ 143,893,750

Confidentially Marketed Follow-on Offering
Medtech Aug 2022
Karuna Follow-on

$ 862,500,000

Follow-on Offering
Biopharma Aug 2022
Invacare SSTL

$ 104,500,000

Senior Secured Term Loan
Medtech Jul 2022
Invacare CN

$ 55,300,000

Exchange of Convertible Notes
Medtech Jul 2022
Natus_ArchiMed MA

$ 1,200,000,000

Mergers & Acquisitions
Medtech Jul 2022
Xenon CMO

$ 250,000,000

Confidentially Marketed Follow-on Offering
HealthTech Jun 2022
Well Health Follow-on

C$ 34,511,565

Follow-on Offering
HealthTech May 2022
Redex Pharma Follow-on

£ 34,261,864

Follow-on Offering
Biopharma May 2022
PepGen

$ 108,000,000

Initial Public Offering
Biopharma May 2022
Integra_Anthem M&A

Mergers & Acquisitions
Healthcare Services May 2022
HilleVax IPO

$ 200,000,000

Initial Public Offering
Biopharma Apr 2022
Nkarta CMO

$ 230,000,000

Confidentially Marketed Follow-on Offering
Biopharma Apr 2022
Hyloris Follow-on

€ 15,000,000

Follow-on Offering
Healthcare Apr 2022
Renalytix

$ 30,000,000

Convertible Bond and Equity Placing
Medtech Mar 2022
IGM Follow-on 03/22

$ 230,000,000

Follow-on Offering
Biopharma Mar 2022
Geron CMO 03/22

$ 75,000,000

Confidentially Marketed Follow-on Offering
Biopharma Mar 2022
Dario Health Registered Direct

$ 40,000,000

Registered Direct
HealthTech Mar 2022
Athenahealth Senior Notes

$ 2,350,000,000

Senior Notes
HealthTech Feb 2022
Zymeworks CMO

$ 100,000,000

Confidentially Marketed Follow-on Offering
Biopharma Jan 2022
Vigil IPO

$ 98,000,000

Initial Public Offering
Biopharma Jan 2022
Mississippi_Retina M&A

Mergers & Acquisitions
Healthcare Services Dec 2021
MEI Pharma Follow-on

$ 52,325,000

Follow-on Offering
Biopharma Dec 2021
Wellhealth

C$ 65,000,000

Convertible Notes
HealthTech Nov 2021
ALSP Orchid SPAC IPO

$ 172,500,000

SPAC IPO
Biopharma Nov 2021
ViewRay CMO

$ 80,500,000

Confidentially Marketed Follow-on Offering
Medtech Nov 2021
Prilenia Private Placement

$ 43,000,000

Private Placement
Biopharma Nov 2021
908 Devices Follow-on

$ 100,800,000

Follow-on Offering
Tools & Diagnostics Nov 2021
Motion_Docgo M&A

$ 158,000,000

Mergers & Acquisitions
HealthTech Nov 2021
BioCare_Vistria M&A

Mergers & Acquisitions
Healthcare Services Nov 2021
Spindletop IPO

$ 230,000,000

Initial Public Offering
Healthcare Services Nov 2021
Sonendo IPO

$ 93,600,000

Initial Public Offering
Medtech Oct 2021
Iveric Bio CMO

$ 150,750,000

Confidentially Marketed Follow-on Offering
Biopharma Oct 2021
Ventripoint Follow-on

C$ 7,004,400

Follow-on Offering
Healthcare & Special Situations Oct 2021
Apollo CMO

$ 74,865,000

Confidentially Marketed Follow-on Offering
Medtech Oct 2021
Xenon Follow-on Offering

$ 345,000,000

Follow-on Offering
Medtech Oct 2021
Zomedica_PulseVet M&A

$ 70,900,000

Mergers & Acquisitions
Medtech Oct 2021
Ekkio_LIM M&A

Mergers & Acquisitions
Medtech Oct 2021
Greenbrook Follow-on

$ 13,200,000

Follow-on Offering
Healthcare Services Sep 2021
Audax M&A

Mergers & Acquisitions
Medtech Sep 2021
Maravai Follow-on

$ 1,000,000,000

Follow-on Offering
Biopharma Sep 2021
Somalogic_CM Life SPAC Merger

$ 651,000,000

SPAC Merger
Tools & Diagnostics Sep 2021
Atlas Antibodies – Afinum – SHS M&A

Mergers & Acquisitions
Biopharma Aug 2021
Surrozen

$ 212,000,000

SPAC Merger & PIPE
Biopharma Aug 2021
Adagio

$ 355,810,000

Initial Public Offering
Biopharma Aug 2021
Rani Therapeutics IPO

$ 84,333,337

Initial Public Offering
Biopharma Jul 2021
Absci IPO

$ 230,000,000

Initial Public Offering
Tools & Diagnostics Jul 2021
BioAgri – DWHP M&A

Mergers & Acquisitions
Biopharma Jul 2021
Gen inCode IPO

£ 17,000,000

Initial Public Offering
HealthTech Jul 2021
Imago Biosciences IPO

$ 174,560,000

Initial Public Offering
Biopharma Jul 2021
Rapidmicro IPO

$ 180,132,080

Initial Public Offering
Tools & Diagnostics Jul 2021
LeMaitre CMO

$ 62,675,000

Confidentially Marketed Follow-on Offering
Medtech Jul 2021
Iveric Bio CMO

$ 100,190,000

Confidentially Marketed Follow-on Offering
Biopharma Jul 2021
Cerevel Follow-on

$ 350,000,000

Follow-on Offering
Biopharma Jul 2021
Nyxoah IPO

$ 97,807,500

Initial Public Offering (U.S. Nasdaq)
Medtech Jul 2021
Vetio Animal – Swedencare M&A

$ 181,500,000

Mergers & Acquisitions
Biopharma Jul 2021
Acumen IPO

$ 160,000,000

Initial Public Offering
Biopharma Jun 2021
GH Research IPO

$ 160,000,000

Initial Public Offering
Biopharma Jun 2021
OneSpaWorld Follow-on

$ 80,000,000

Follow-on Offering
Entertainment Jun 2021
RCSA M&A

Mergers & Acquisitions
Healthcare Services Jun 2021
Outset Medical – Follow-on Offering

$ 366,000,000

Follow-on Offering
Medtech Apr 2021
Evolus 04-2021

$ 98,325,000

Confidentially Marketed Follow-on Offering
Biopharma Apr 2021
SeaSpine Holdings 04-2021

$ 100,912,500

Confidentially Marketed Follow-on Offering
Medtech Apr 2021
Karuna Therapeutics Follow-on Offering

$ 287,500,000

Follow-on Offering
Biopharma Apr 2021
Maravai Life Sciences 04-2021

$ 646,875,000

Follow-on Offering
Tools & Diagnostics Apr 2021
Ionis Pharmaceuticals 04-2021

$ 550,000,000

Convertible Senior Notes
Biopharma Apr 2021
ProQR Therapeutics 03-2021

$ 103,500,000

Confidentially Marketed Follow-on Offering
Biopharma Mar 2021
Cti Biopharma 03-2021

$ 50,652,000

Confidentially Marketed Follow-on Offering
Biopharma Mar 2021
Evofem Biosciences 03-2021

$ 30,000,000

Confidentially Marketed Follow-on Offering
Biopharma Mar 2021
AVEO Oncology 03-2021

$ 48,000,000

Follow-on Offering
Biopharma Mar 2021
PhaseBio Pharmaceuticals 03-2021

$ 56,000,000

Confidentially Marketed Follow-on Offering
Biopharma Mar 2021
X4 Pharmaceuticals – PIPE

$ 55,000,000

PIPE
Biopharma Mar 2021
Prometheus Biosciences 03-2021

$ 218,500,000

Initial Public Offering
Biopharma Mar 2021
Xenon Pharmaceuticals 03-2021

$ 115,000,000

Confidentially Marketed Follow-on Offering
HealthTech Mar 2021
Nurix Follow-on Offering

$ 160,425,000

Follow-on Offering
Biopharma Mar 2021
Cutera – Convertible Notes

$ 138,250,000

Convertible Notes
Medtech Mar 2021
Squadron – Alphatec M&A

$ 90,000,000

Has Invested in
Medtech Mar 2021
KalVista 02-2021

$ 222,250,000

Follow-on Offering
HealthTech Feb 2021
SQZ Biotechnologies 02-2021

$ 60,000,000

Follow-on Offering
HealthTech Feb 2021
Centene – Senior Notes

$ 2,200,000,000

Senior Notes
Healthcare Services Feb 2021
Rhythm Pharmactuticals 02-2021

$ 150,000,000

Follow-on Offering
HealthTech Feb 2021
Sientra – Confidentially Marketed Follow-on Offering

$ 42,000,000

Confidentially Marketed Follow-on Offering
Medtech Feb 2021
Bolt Biotherapeutics 02-2021

$ 264,500,000

Initial Public Offering
Biopharma Feb 2021
Vor Biopharma 02-2021

$ 203,439,942

Initial Public Offering
Biopharma Feb 2021
Angion Biomedica Corp 02-2021

$ 117,000,000

Initial Public Offering
Biopharma Feb 2021
Gemini – SPAC Merger & PIPE

SPAC Merger & PIPE
Biopharma Feb 2021
MaxCyte – PIPE

£ 40,000,000

PIPE
Biopharma Feb 2021
Applied Genetic Technnologies 02-2021

$ 74,500,000

Confidentially Marketed Follow-on Offering
Biopharma Feb 2021
DarioHealth Group 02-2021

$ 70,000,000

Private Placement
HealthTech Feb 2021
Precigen 01-2021

$ 129,375,000

Confidentially Marketed Follow-on Offering
Biopharma Jan 2021
Dyne Therapeutics 01-2021

$ 168,000,000

Follow-on Offering
Biopharma Jan 2021
Athira Pharma 01-2021

$ 103,500,000

Follow-on Offering
Biopharma Jan 2021
AdaptHealth Crop 01-2021

$ 264,000,000

Follow-on Offering
Healthcare Services Jan 2021
AbCellera Biologics 12-2020

$ 555,450,000

Initial Public Offering
Biopharma Dec 2020
908 Devices 12-2020

$ 149,500,000

Initial Public Offering
Tools & Diagnostics Dec 2020
IGM Biosciences 12-2020

$ 200,000,000

Follow-on Offering
Biopharma Dec 2020
Kura Oncology 12-2020

$ 345,080,500

Follow-on Offering
Biopharma Dec 2020
Repligen 12-2020

$ 312,225,000

Follow-on Offering
Tools & Diagnostics Dec 2020
Codexis 12-2020

$ 750,000,000

Follow-on Offering
Tools & Diagnostics Dec 2020
Silverback Therapeutics 12-2020

$ 277,725,000

Initial Public Offering
Biopharma Dec 2020
Maravai Life Science, Inc. 11-2020

$ 1,863,000,000

Initial Public Offering
Tools & Diagnostics Nov 2020
SQZ Biotechnologies 11-2020

$ 81,176,464

Initial Public Offering
Biopharma Nov 2020
Lux Health Tech Acquisition Corp. 10-2020

$ 345,000,000

Initial Public Offering
Medtech Oct 2020
Eucrates Biomedical 10-2020

$ 104,796,260

Initial Public Offering
Medtech Oct 2020
Ionis/Akcea 10-2020

$ 1,898,938,296

Mergers & Acquisitions
Biopharma Oct 2020
Pulmonx Corporation 10-2020

$ 2,128,500,000

Initial Public Offering
Medtech Oct 2020
Zogenix 09-2020

$ 200,000,000

Convertible Notes
Biopharma Sep 2020
Athira Pharma 09-2020

$ 277,761,104

Initial Public Offering
Biopharma Sep 2020
Dyne Therapeutics 09-2020

$ 267,696,966

Initial Public Offering
Biopharma Sep 2020
Horizon Therapeutics 08-2020

$ 963,470,000

Follow-on Offering
Biopharma Aug 2020
Elanco/Vetoquinol 08-2020

$ 140,000,000

Mergers & Acquisitions
Biopharma Aug 2020
Elanco/Vetoquinol 08-2020

$ 140,000,000

Mergers & Acquisitions
Biopharma Aug 2020
Dechra Pharmaceuticals/Elanco Animal Health Inc. 07-2020

$ 135,000,000

Mergers & Acquisitions
Biopharma Jul 2020
Cerevel Therapeutics 07-2020

$ 445,000,000

PIPE
Biopharma Jul 2020
Nurix Therapeutics 07-2020

$ 209,000,000

Initial Public Offering
Biopharma Jul 2020
Genocea BioSciences 07-2020

$ 80,000,000

PIPE
Biopharma Jul 2020
Atreca 07-2020

$ 120,000,000

Confidentially Marketed Follow-on Offering
Biopharma Jul 2020
Orthopediatrics_Apifix M&A

$ 39,054,798

Mergers & Acquisitions
Medtech Apr 2020
Compugen CMO

$ 79,347,051

Confidentially Marketed Follow-on Offering
Biopharma Mar 2020
Moksha8

$ 125,000,000

Strategic Financing Agreement
Biopharma Feb 2019
Lilly_Uniao Quimica MA

Mergers & Acquisitions
Biopharma Sep 2018
Currency volume represents full credit to each underwriter. All transaction announcements appear as a matter of record only. Stifel collectively refers to Stifel, Nicolaus & Company, Incorporated and other affiliated broker-dealer subsidiaries of Stifel Financial Corp.